Your browser is no longer supported. Please, upgrade your browser.
Settings
LYEL [NASD]
Lyell Immunopharma, Inc.
Index- P/E- EPS (ttm)- Insider Own2.70% Shs Outstand242.83M Perf Week9.12%
Market Cap3.66B Forward P/E- EPS next Y-1.29 Insider Trans0.00% Shs Float200.53M Perf Month18.30%
Income- PEG- EPS next Q-0.27 Inst Own31.20% Short Float2.13% Perf Quarter12.44%
Sales8.46M P/S433.21 EPS this Y-58.00% Inst Trans0.52% Short Ratio9.84 Perf Half Y-
Book/sh4.21 P/B3.61 EPS next Y9.80% ROA- Target Price25.50 Perf Year-
Cash/sh3.42 P/C4.44 EPS next 5Y-7.90% ROE- 52W Range10.62 - 19.84 Perf YTD-10.07%
Dividend- P/FCF- EPS past 5Y- ROI72.40% 52W High-23.44% Beta-
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low43.03% ATR1.01
Employees188 Current Ratio13.10 Sales Q/Q-15.70% Oper. Margin- RSI (14)61.14 Volatility5.10% 8.53%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.53 Prev Close14.45
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume433.96K Price15.19
Recom1.70 SMA2013.80% SMA507.73% SMA2002.67% Volume231,701 Change5.12%
Jul-12-21Initiated Morgan Stanley Overweight $25
Jul-12-21Initiated JP Morgan Overweight $22
Jul-12-21Initiated Goldman Buy $30
Jul-12-21Initiated BofA Securities Buy $25
Sep-30-21 06:01PM  
Sep-17-21 10:16AM  
Sep-08-21 04:05PM  
Aug-12-21 04:05PM  
Jul-18-21 11:39AM  
Jul-01-21 02:46PM  
Jun-17-21 05:29PM  
05:26PM  
01:02PM  
Jun-16-21 09:49PM  
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.